Navigation Links
Mount Sinai's Arvin Dar, Ph.D., receives NIH New Innovator Award for drug development

Arvin Dar, PhD, structural and chemical biologist in oncological sciences at the Icahn School of Medicine at Mount Sinai, is one of 41 national recipients of the prestigious National Institutes of Health (NIH) Director's New Innovator Awards for High-Risk, High Reward Research. The award will support Dar's research into Ras-dependent cancers, specifically investigating how to combat mutations in Ras, a protein implicated in at least one of every five cancers.

Even though Ras mutations have long been known as critical drivers of cancer, metastasis, and resistance to chemotherapy, drug development in this area has been dissappointing. It turns out that the structural biology underlying Ras mutations is extremely complex.

Dr. Dar, along with other researchers at the Icahn School of Medicine at Mount Sinai and the University of California San Francisco have been instrumental in advancing this research.

Dr. Dar's laboratory has been investigating new targets or strategies that show promise in interrupting the Ras pathway. The work is highly interdisciplinary, incorporating methods from synthetic organic chemistry, mass spectrometry, informatics, biochemistry, and model organism genetics. The eventual goal is to produce new classes of small molecule drugs that impede cancers.

"NIH is excited to support visionary investigators," said NIH Director Francis S. Collins, MD, PhD. This research has "the potential to transform scientific fields and accelerate the translation of scientific research into improved health."

The NIH Common Fund, in partnership with other NIH Institutes, are key backers of the NIH Director's New Innovators Fund. These programs are designed to overcome major research barriers, specifically catalyzing disease-specific research.

In accepting the award, Dr. Dar said: "It is truly an honor to be included in this year's recipients as it is a highly competitive funding mechanism. I have benefited greatly from support and mentorship of Mount Sinai faculty, including Stuart Aaronson and Ross Cagan, as well as my postdoctoral advisor, Kevan Shokat, at the University of California San Francisco. My previous work with them has led to a compound that is currently progressing towards a human clinical trial, and this new funding will allow us to explore new avenues in drug therapy."

Thirty years ago, Mount Sinai researchers played a pivotal role in first discovering Ras mutations, and their relationship to cancer biology. Stuart Aaronson, PhD, and Prem Reddy, PhD, made significant inroads in uncovering Ras mutations.


Contact: Mount Sinai Press Office
The Mount Sinai Hospital / Mount Sinai School of Medicine

Related medicine news :

1. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
2. Lipitor Lawsuits Continue to Mount, as Bernstein Liebhard LLP Notes Filing of New Claim Alleging an Association Between Lipitor and Diabetes
3. Mount Sinai's Novel Gene Therapy Works to Reverse Heart Failure
4. Mount Sinai Makes Innovation a Team Effort At Its Second Annual Sinainnovations Conference, November 18-19, 2013 In NYC
5. Mount Sinai Dermatology Department in NY Opens New Practice in Chinatown
6. Pradaxa Lawsuits Continue to Mount, With Filing of New Pradaxa Wrongful Death Claim in Pennsylvania by Wright & Schulte LLC
7. National Association of Professional Women Announces Elizabeth C. Abel, M.S.W., Project Director, CAPP of City of Mount Vernon-Youth Bureau, as VIP Woman of the Year
8. Newcastle, Oklahoma High School Provides Football Team with Brain Sentry Impact Sensor, Helmet-Mounted Device Helps ID Players Who Need to be Evaluated for Concussion
9. Peter R. Dottino, MD to Head Division of Gynecologic Oncology at Mount Sinai
10. Mirena Lawsuits Mount, as Bernstein Liebhard LLP Notes More than 400 Mirena IUD Lawsuit Filings in State, Federal Litigations
11. Mount Sinai and the Atlantic Host Working Summit on Big Data in New York City
Post Your Comments:
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the world-class ... improve system efficiency and reliability. , The new Q-Suite 6 platform is based on ... avoids locking itself into a specific piece of software for many key components of ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... Finnleo, ... through Christmas Eve on several models of traditional and far-infrared saunas. , ... Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European ...
(Date:11/25/2015)... ... November 25, 2015 , ... TyloHelo Inc , ... accessories. , Sauna accessories help improve the bather experience in the sauna, and ... styles for the purist looking for simplicity in design to accessories that encourage ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... $15.8  Million to expand its laboratories and global ... The expansion will provide additional office space and ... of the pharmaceutical and biotechnology markets. ... up to 40,000 square feet of expanded development ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
Breaking Medicine Technology: